Tango Therapeutics, Inc. officer Adam Crystal filed a Form 144 notice of proposed sale with the SEC on November 2, 2026, covering 20,000 shares of common stock to be sold on NASDAQ.
Key Highlights
- Proposed sale: Adam Crystal, an officer of Tango Therapeutics, Inc., intends to sell 20,000 shares of common stock with an aggregate market value of $454,400.00.
- Acquisition method: The 20,000 shares were acquired through the exercise of stock options from the issuer on November 2, 2026, with payment made in cash.
- Shares outstanding: According to the filing, 168,610,367 shares of common stock were outstanding at the time of the notice.
- 10b5-1 plan: The filing indicates a Rule 10b5-1 trading plan was adopted on June 10, 2026.
- Prior three-month sales: Crystal sold 27,000 shares on October 1, 2026 (gross proceeds $660,797.10), 27,000 shares on September 1, 2026 (gross proceeds $603,910.20), and 27,000 shares on August 3, 2026 (gross proceeds $735,518.10), all under 10b5-1 plan sales.
- Broker: The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
Adam Crystal's Proposed Share Sale at Tango Therapeutics: Filing Details
Tango Therapeutics, Inc. (NASDAQ:TNGX) officer Adam Crystal filed a Form 144 notice dated November 2, 2026, disclosing a proposed sale of 20,000 shares of the company's common stock. According to the filing, the aggregate market value of the shares to be sold is $454,400.00, and the approximate date of sale is listed as November 2, 2026. The securities are to be sold on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services.
The filing states that the 20,000 shares subject to the proposed sale were acquired on November 2, 2026, via the exercise of stock options from the issuer, with cash payment made on the same date. The remarks section of the filing notes: "The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale." The filing also indicates that Crystal is relying on a Rule 10b5-1 trading plan adopted on June 10, 2026.
With respect to sales during the prior three months, the filing reports three separate 10b5-1 transactions by Crystal: 27,000 shares sold on October 1, 2026 for gross proceeds of $660,797.10; 27,000 shares sold on September 1, 2026 for gross proceeds of $603,910.20; and 27,000 shares sold on August 3, 2026 for gross proceeds of $735,518.10. The total shares outstanding reported in the filing are 168,610,367.
What Was Disclosed
Tango Therapeutics officer Adam Crystal filed a Form 144 on November 2, 2026, proposing to sell 20,000 shares of common stock valued at $454,400.00 on NASDAQ, acquired through stock option exercises under a 10b5-1 plan adopted June 10, 2026.



Please wait processing your request...